Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Timing of Renal Replacement Therapy in Hypervolemic Cardiogenic Shock

NCT07756801 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT07756801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07756801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Timing of Renal Replacement Therapy in Hypervolemic Cardiogenic Shock
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2031
Enrollment
456 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiogenic shock, hypervolemia, renal replacement therapies